[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336091-105":59,"doc-detail-336091-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","oncolytic-adenovirus-armed-with-a-novel-agonist-of-the-cd137-immune-checkpoint-stimulator-suppresses-tumor-growth","Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth","","Natural 4-1BBL (CD137L) drives CD8+ T-cell expansion, effector function, and survival. The study describes SA-4-1BBL and an oncolytic adenovirus platform (OAdSA-4-1BBL) designed to deliver and express SA-4-1BBL in solid tumors for immunotherapy. The construct induced T-cell proliferation in vitro, reduced viability of TC-1 and CMT64 lung cancer cells, and triggered apoptosis and autophagy with ATP release. Intratumoral dosing in a TC-1 syngeneic model suppressed tumors and enhanced dendritic cell frequency and infiltration of cytotoxic CD8+ T and NK cells. Results support OAdSA-4-1BBL as a standalone or combination strategy for lung cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oncolytic-adenovirus-armed-with-a-novel-agonist-of-the-cd137-immune-checkpoint-stimulator-suppresses-tumor-growth/336091/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oncolytic-adenovirus-armed-with-a-novel-agonist-of-the-cd137-immune-checkpoint-stimulator-suppresses-tumor-growth/336091.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the role of CD137L (4-1BBL) in antitumor immunity?","Question",{"text":112,"@type":113},"CD137L is a costimulatory molecule needed for CD8+ T-cell expansion and for generating effector and memory responses required to fight tumor cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does OAdSA-4-1BBL work in the proposed immunotherapy approach?",{"text":117,"@type":113},"The oncolytic adenovirus delivers and induces expression of the SA-4-1BBL protein inside solid tumors, aiming to combine tumor cell killing with immune activation.",{"name":119,"@type":110,"acceptedAnswer":120},"What effects did OAdSA-4-1BBL show in cancer models?",{"text":121,"@type":113},"In vitro, it reduced viability of TC-1 and CMT64 lung cancer cells and induced apoptosis and autophagy with ATP release. In vivo, intratumoral injection suppressed tumors and increased dendritic cells and infiltration of cytotoxic CD8+ T and NK cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336091,1790171102,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Article  \nOncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth  \nMartin R. Ramos-Gonzalez 1,2, Mohammad Tarique 1, Lalit Batra 3, Feyza Arguc 1, Rodolfo Garza-Morales 4, Haval Shirwan 1,2,5, Esma S. Yolcu 1,2,5 and Jorge G. Gomez-Gutierrez 1,2,5, *  \nCitation: Ramos-Gonzalez, M.R.; Tarique, M.; Batra, L.; Arguc, F.; Garza-Morales, R.; Shirwan, H.; Yolcu, E.S.; Gomez-Gutierrez, J.G. Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth. Vaccines 2024, 12, 340 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)vaccines12030340  \nAcademic Editors: François Meurensand Craig Meyers  \nReceived: 20 January 2024  \nRevised: 18 March 2024  \nAccepted: 18 March 2024  \nPublished: 21 March 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Roy Blunt NextGen Precision Health Building, University of Missouri, Columbia, MO 65211, USA; [mr.ramos@health.missouri.edu](mr.ramos@health.missouri.edu) (M.R.R.-G.); [mohammad.tarique@health.missouri.edu](mohammad.tarique@health.missouri.edu) (M.T.); [f.arguc@health.missouri.edu](f.arguc@health.missouri.edu) (F.A.); [haval.shirwan@health.missouri.edu](haval.shirwan@health.missouri.edu) (H.S.); [esma.yolcu@health.missouri.edu](esma.yolcu@health.missouri.edu) (E.S.Y.)  \n2 Ellis Fischel Cancer Center, University of Missouri, Columbia, MO 65212, USA  \n3 Regional Biocontainment Laboratory, Center for Predictive Medicine, University of Louisville, Louisville, KY 40222, USA; [lalit.batra@louisville.edu](lalit.batra@louisville.edu)  \n4 Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA; [garzamorales.rodolfo@mayo.edu](garzamorales.rodolfo@mayo.edu)  \n5 Department of Pediatrics, University of Missouri, Columbia, MO 65212, USA  \n* [Correspondence: jgdk2@health.missouri.edu](Correspondence: jgdk2@health.missouri.edu)  \nAbstract: Natural 4-1BBL (CD137L) is a cell membrane-bound protein critical to the expansion, effector function, and survival of CD8+ T cells. We reported the generation of an active soluble oligomeric construct, SA-4-1BBL, with demonstrated immunoprevention and immunotherapeutic efficacy in various mouse tumor models. Herein, we developed an oncolytic adenovirus (OAd) for the delivery and expression of SA-4-1BBL (OAdSA-4-1BBL) into solid tumors for immunotherapy. SA-4-1BBL protein expressed by this construct produced T-cell proliferation in vitro. OAdSA-4-1BBL decreased cell viability in two mouse lung cancer cell lines, TC-1 and CMT64, but not in the noncancerous lung MM14.Lu cell line. OAdSA-4-1BBL induced programmed cell death types I and II (apoptosis and autophagy, respectively), and autophagy-mediated adenosine triphosphate (ATP) release was also detected. Intratumoral injection of OAdSA-4-1BBL efficiently expressed the SA-4- 1BBL protein in the tumors, resulting in significant tumor suppression in a syngeneic subcutaneous TC-1 mouse lung cancer model. Tumor suppression was associated with a higher frequency of dendritic cells and an increased infiltration of cytotoxic CD8+ T and NK cells into the tumors. Our data suggest that OAdSA-4-1BBL may present an efficacious alternative therapeutic strategy against lung cancer as a standalone construct or in combination with other immunotherapeutic modalities, such as immune checkpoint inhibitors.  \nKeywords: oncolytic; adenovirus; SA-4-1BBL; lung; cancer; immunotherapy  \n1. Introduction  \n4-1BBL (CD137L) is as a costimulatory molecule required for appropriate T-cell expansion, inducing the effector and memory responses in CD8+ T cells, a mechanism required fo","cbCaijXabzXsYx9h","https://ap.wps.com/l/cbCaijXabzXsYx9h","pdf",4687478,17,"English","# Abstract\n# Introduction\n## CD137L biology and SA-4-1BBL background\n## Oncolytic virotherapy rationale\n## Oncolytic adenoviruses as delivery platform","[{\"question\":\"What is the role of CD137L (4-1BBL) in antitumor immunity?\",\"answer\":\"CD137L is a costimulatory molecule needed for CD8+ T-cell expansion and for generating effector and memory responses required to fight tumor cells.\"},{\"question\":\"How does OAdSA-4-1BBL work in the proposed immunotherapy approach?\",\"answer\":\"The oncolytic adenovirus delivers and induces expression of the SA-4-1BBL protein inside solid tumors, aiming to combine tumor cell killing with immune activation.\"},{\"question\":\"What effects did OAdSA-4-1BBL show in cancer models?\",\"answer\":\"In vitro, it reduced viability of TC-1 and CMT64 lung cancer cells and induced apoptosis and autophagy with ATP release. In vivo, intratumoral injection suppressed tumors and increased dendritic cells and infiltration of cytotoxic CD8+ T and NK cells.\"}]","Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth | PDF",1790013561,43]